Literature DB >> 12794617

Current and evolving strategies for colorectal cancer screening.

James Helm1, Junsung Choi, Rebecca Sutphen, James S Barthel, Terrance L Albrecht, Thomas N Chirikos.   

Abstract

BACKGROUND: Colorectal cancer is a major cause of cancer mortality and morbidity. Screening can potentially prevent most colorectal cancers by detection and removal of precursor adenomas.
METHODS: The literature and clinical practice guidelines are reviewed, with an emphasis on advances of the last 10 years and evolving screening methods.
RESULTS: Colonoscopy has come to be used for screening in persons at average risk for colorectal cancer because of the comparative ineffectiveness of other methods, although these methods continue to be recommended. Virtual colonoscopy and fecal DNA testing are emerging technologies with promise to be more effective than fecal occult blood testing or sigmoidoscopy in selecting those persons who should undergo colonoscopy. Next to age, family history is the most common risk factor for colorectal cancer and one that warrants more aggressive screening and, in some instances, genetic counseling and testing. Hereditary nonpolyposis colorectal cancer accounts for as many as 1 in 20 colorectal cancers, but to take advantage of recent advances in genetic testing for this disorder, a high level of clinical suspicion must be maintained.
CONCLUSIONS: If we are to reduce mortality and morbidity from colorectal cancer, practicing clinicians need to be aware of current and evolving strategies for colorectal screening, and assertively recommend the appropriate strategy to their patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12794617     DOI: 10.1177/107327480301000302

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  4 in total

Review 1.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

2.  Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening.

Authors:  Wen Meng; Hong-Hong Zhu; Ze-Feng Xu; Shan-Rong Cai; Qi Dong; Qiang-Rong Pan; Shu Zheng; Su-Zhan Zhang
Journal:  World J Gastrointest Oncol       Date:  2012-06-15

3.  Clinical features of colorectal cancer detected by the national cancer screening program.

Authors:  Dae-Do Park; Rumi Shin; Ji-Sun Kim; Heung-Kwon Oh; Seung-Yong Jeong; Kyu Joo Park; Jae-Gahb Park
Journal:  J Korean Soc Coloproctol       Date:  2010-12-31

4.  Low expression of chloride channel accessory 1 predicts a poor prognosis in colorectal cancer.

Authors:  Bo Yang; Lin Cao; Jiaen Liu; Yanjie Xu; Gillian Milne; Wanhei Chan; Steven D Heys; Colin D McCaig; Jin Pu
Journal:  Cancer       Date:  2015-01-20       Impact factor: 6.860

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.